Cti Biopharma Investors
CTI BioPharma is a company that focuses on developing and selling cancer treatment products. One of its main products in development is Pixantrone, which is currently in phase III trials and is intended for non-Hodgkin's lymphoma.
Estimated Revenue:
$1M to $10M
Investor Type:
Funds of Funds
Industry:
AgeTech and Assistive Tech
Founded Date:
1991